Azmi Nabulsi is COO at Phathom Pharmaceuticals, Inc. (PHAT). They have made 12 open-market trades across 1 company since 2020, most recently 2025-02-27.
CIK 0001791412
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $246K since 2022, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PHAT | 312,590 | $2.2M |
Shares reported on the most recent Form 4, priced at the 2025-03-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PHAT | SELL | 2025-01-21 | 2025-01-23 | $6.59 | $104K | -15.4% | -25.3% | -43.8% |
| PHAT | SELL | 2024-12-19 | 2024-12-20 | $8.00 | $9K | +4.3% | -8.5% | -15.6% |
| PHAT | SELL | 2024-07-15 | 2024-07-17 | $11.72 | $256K | -3.7% | +4.6% | +31.6% |
| PHAT | BUY | 2023-04-11 | 2023-04-11 | $8.26 | $83K | +24.6% | +55.4% | +64.6% |
| PHAT | BUY | 2022-05-16 | 2022-05-16 | $8.16 | $163K | -14.7% | -24.6% | +32.9% |
| PHAT | SELL | 2021-05-03 | 2021-05-04 | $37.84 | $1.1M | -7.4% | -7.6% | -11.0% |
| PHAT | SELL | 2021-04-01 | 2021-04-05 | $36.61 | $1.0M | +3.8% | -1.9% | -2.0% |
| PHAT | SELL | 2021-03-01 | 2021-03-03 | $45.95 | $1.2M | -2.1% | -21.7% | -21.5% |
| PHAT | SELL | 2021-02-01 | 2021-02-03 | $39.83 | $1.0M | +0.2% | +7.4% | -15.6% |
| PHAT | SELL | 2020-12-01 | 2020-12-03 | $44.74 | $1.3M | +10.6% | -25.5% | +0.9% |
| PHAT | SELL | 2020-11-02 | 2020-11-03 | $36.83 | $534K | +3.7% | +16.2% | -1.6% |
| PHAT | SELL | 2020-01-04 | 2021-01-05 | $33.60 | $971K | +7.1% | +24.2% | +2.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.